A health-tech founder pitching a remote monitoring platform to an NHS trust board will usually get further with a compelling clinical evidence pack than with a healthy balance sheet. That is the uncomfortable truth sitting behind Rachel Reeves's announcement of £500m in additional funding for the British Business Bank's Growth Guarantee Scheme, unveiled the day before her Mansion House speech and framed as a fix for the £1.6bn to £4.1bn annual gap between SME demand for finance and the funding actually available.

The scheme itself is a reasonable piece of machinery. Loan guarantees at 70 per cent, terms extended from six to ten years, an eligibility ceiling raised to £54m in turnover, all of it should make borrowing marginally easier for growing businesses across every sector. For a manufacturer or a logistics firm needing working capital to expand, that matters. For the digital health companies that ministers routinely cite as evidence of Britain's life sciences ambition, it addresses a constraint that rarely determines whether they succeed.

The real barrier for health-tech SMEs is not the availability of debt. It is the buyer. NHS procurement remains fragmented across integrated care boards and individual trusts, each with its own risk appetite, its own information governance sign-off, and its own appetite for pilots that never convert into contracts. A company can raise every pound the Growth Guarantee Scheme allows and still spend eighteen months negotiating a single trust-level deployment, only to find the neighbouring ICB wants to start the evaluation from scratch. This is the pattern that has shaped the electronic patient record procurement cycle, the slow rollout of ambient voice technology under emerging MHRA guidance, and the persistent gap between NICE approving a product and that product reaching patients at scale. Capital shortens the runway. It does not shorten the sales cycle.

There is a version of this announcement that would have mattered more directly to health-tech, one that paired financing reform with a commitment to a single national adoption pathway or a standing NHS procurement framework that let a product proven in one trust be adopted elsewhere without re-litigating the evidence. That version does not exist yet. What exists is a supply-side intervention aimed at a demand-side problem, and the distinction is not academic. Ministers have spent the past year emphasising life sciences as a growth sector and NHS digital transformation as a delivery priority, from the Federated Data Platform rollout to the drive toward Advanced Foundation Trust status for better-performing organisations. Each of those initiatives depends on the NHS behaving as a coherent, confident buyer. Each of them is undermined by the same procurement fragmentation that guaranteed loans cannot touch.

None of this means the scheme is misconceived. Reeves is right that small businesses have too often heard no when seeking finance, and a better-capitalised SME sector benefits the wider economy regardless of which industry absorbs the funding. The error lies in the implicit assumption, visible in the framing rather than stated outright, that access to capital is the universal constraint on scale-up growth. For sectors selling into a single dominant public purchaser, that assumption breaks down.

The test of whether this expansion helps British health-tech will not be measured in loans issued but in whether any of that additional lending translates into products actually deployed inside the NHS. If procurement remains as fragmented in twelve months as it is today, the likely outcome is a cohort of better-funded companies facing precisely the same adoption bottleneck, only with more debt on their books while they wait. Ministers keen to claim credit for backing innovation might ask themselves which side of that equation they have actually fixed.